Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosinophilic asthma who participated in the COSMOS trial, where patients received mepolizumab for more than 1 year of continuous therapy. The objective of this post hoc analysis was to evaluate changes in the Asthma Control Questionnaire (ACQ-5) and blood eosinophil counts 12 weeks after the last administration of mepolizumab. Cessation of mepolizumab was associated with a rise in the blood eosinophil count and loss of asthma control after stopping therapy. These data suggest that patients with severe disease require extended and continuous treatment. Further studies evaluating longer duration of continuous treatment with mepolizumab could help understanding of whether changes in the presentation of the disease (disease modification) are possible with the use of biologics, such as mepolizumab.

中文翻译：

---

美泊珠单抗治疗中止后的结果：一项开放标签试验的真实经验

停止生物治疗后重症哮喘患者的临床病程信息有限。因此，对参加COSMOS试验的重度嗜酸性哮喘患者进行了事后分析，其中患者接受美泊利单抗治疗超过一年。这项事后分析的目的是评估哮喘控制问卷（ACQ-5）的变化和上次给予美泊珠单抗12周后的血液嗜酸性粒细胞计数。停止治疗后，Mepolizumab的中止与血液嗜酸性粒细胞计数的增加和哮喘控制的丧失有关。这些数据表明，患有严重疾病的患者需要长期和持续的治疗。